Table of Contents
Washington University Experience | NEOPLASMS (HEMATOLYMPHOID) | Lymphoma, immune-compromised | 14D1 Lymphoma, 6 mo imm-supp (Case 145) CD20 4X.jpg
14D1-3 Immunohistochemistry shows the tumor cells are strongly and diffusely positive for the B-cell lymphocyte marker CD20. CD20 immunoreactivity is also preserved in the lower necrotic part of the specimen (CD20 IHC)
